3 Drugs Stocks Pushing Industry Growth

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 7 points (0.0%) at 17,640 as of Monday, Oct. 26, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,119 issues advancing vs. 1,864 declining with 145 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Endo International ( ENDP), up 4.5%, Mylan ( MYL), up 2.5%, Incyte ( INCY), up 2.3%, Perrigo ( PRGO), up 2.2% and Regeneron Pharmaceuticals ( REGN), up 2.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $3.53 (2.3%) to $159.28 on average volume. Thus far, 2.3 million shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $154.65-$159.72 after having opened the day at $156.00 as compared to the previous trading day's close of $155.75.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $115.5 billion and is part of the health care sector. Shares are down 2.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Allergan ( AGN) is up $3.76 (1.4%) to $272.31 on average volume. Thus far, 2.4 million shares of Allergan exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $262.52-$278.20 after having opened the day at $262.52 as compared to the previous trading day's close of $268.55.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $99.6 billion and is part of the health care sector. Shares are up 4.3% year-to-date as of the close of trading on Friday. Currently there are 15 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates Allergan as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Allergan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.75 (1.6%) to $109.74 on average volume. Thus far, 5.1 million shares of Gilead exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $107.44-$110.36 after having opened the day at $108.65 as compared to the previous trading day's close of $107.99.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $157.9 billion and is part of the health care sector. Shares are up 14.6% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

A Hungry Grizzly Bear Is Stalking the Stock Market

A Hungry Grizzly Bear Is Stalking the Stock Market

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Why Most Americans Like a Volatile Stock Market: Study

Why Most Americans Like a Volatile Stock Market: Study

Should Retirees Invest in the Tech Sector?

Should Retirees Invest in the Tech Sector?

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings